How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,908 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Biological therapies for psoriasis do not increase serious infection risk

Biological therapies for psoriasis do not increase serious infection risk Biological therapies for psoriasis do not increase serious infection risk Discover Portal Discover Portal Biological therapies for psoriasis do not increase serious infection risk Published on 23 January 2018 doi: People with psoriasis who take an immune-modulating treatment are no more likely to get serious infections than people taking standard therapies. There are fears that these biological therapies raise the risk (...) of serious infections and this has discouraged their use. They are recommended by NICE for moderate to severe psoriasis. Previous studies have reached conflicting conclusions, making it hard to advise on the true risk. This study used a large database of people with psoriasis from the UK and Ireland. It compared serious infection risk of the biological therapies (etanercept, adalimumab or ustekinumab) with non-biological therapies, after accounting for factors such as other illnesses. It found none

2018 NIHR Dissemination Centre

142. Topical steroids better than vitamin D for treating scalp psoriasis

Topical steroids better than vitamin D for treating scalp psoriasis Topical steroids better than vitamin D for treating scalp psoriasis Discover Portal Discover Portal Topical steroids better than vitamin D for treating scalp psoriasis Published on 14 June 2016 doi: Topical steroids applied to the scalp were more effective and safer for treating psoriasis than topical vitamin D alone. Using steroids in combination with vitamin D was statistically better than using a steroid alone (...) , but the difference was not considered clinically important. The combination ointment costs almost £20 for 30g compared to a 30g tube of typical steroid ointment which costs about £4. Scalp psoriasis is a common condition that can be itchy and embarrassing for many. A variety of topical lotions, solutions or gels are available to treat the condition, so this review of published research aimed to help doctors and patients find out which was the most effective and safest option. This systematic review found 59

2018 NIHR Dissemination Centre

143. Ustekinumab (Stelara) - for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients

Ustekinumab (Stelara) - for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA455) NICE GUIDANCE ISSUED JULY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Final Appraisal Recommendation Advice No: 0416 – February 2016 Ustekinumab (Stelara ® ) 45 mg solution for injection, 45 mg and 90 mg solution for injection in pre-filled (...) available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years. Recommendation of AWMSG Ustekinumab (Stelara ® ) is recommended as an option for use within NHS Wales for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled

2016 All Wales Medicines Strategy Group

144. Topical treatments for scalp psoriasis. Full Text available with Trip Pro

Topical treatments for scalp psoriasis. People with chronic plaque psoriasis often have lesions on the scalp. Hair makes the scalp difficult to treat and the adjacent facial skin is particularly sensitive to topical treatments.To assess the efficacy and safety of topical treatments for scalp psoriasis.We searched the following databases up to August 2015: the Cochrane Skin Group Specialised Register, CENTRAL (2015, Issue 7), MEDLINE (from 1946), EMBASE (from 1974) and LILACS (from 1982). We (...) also searched five trials registers, screened abstracts of six psoriasis-specific conferences and checked the reference lists of included studies for further references to relevant randomised controlled trials.Randomised controlled trials (RCTs) with a parallel-group, cross-over or within-patient design of topical treatments for people of all ages with scalp psoriasis.Two authors independently carried out study selection, data extraction and 'Risk of bias' assessment. Disagreements were settled

2016 Cochrane

145. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Full Text available with Trip Pro

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review

2019 EvidenceUpdates

146. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. (Abstract)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis.IMMvent was a phase 3, randomised (...) , double-blind, active-comparator-controlled trial completed at 66 clinics in 11 countries. Eligible patients were aged 18 years or older with moderate-to-severe chronic plaque psoriasis. Patients were randomly assigned 1:1 using interactive response technology to receive 150 mg risankizumab subcutaneously at weeks 0 and 4 or 80 mg adalimumab subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during a 16-week double-blind treatment period (part A). For weeks

2019 Lancet Controlled trial quality: predicted high

147. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. (Abstract)

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab. The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab.In (...) this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy. Eligible patients were randomly assigned with permuted block randomisation using an interactive web response system to receive either

2019 Lancet Controlled trial quality: predicted high

148. Infliximab (Inflectra) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis

Infliximab (Inflectra) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis Final Appraisal Recommendation Advice No: 4214 – December 2014 Infliximab (Inflectra ® ? ) 100 mg powder for concentrate for solution for infusion Submission by Hospira UK Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. ? Please refer to the NICE website for full guidance on NICE recommendations, including any (...) specific restrictions on the use of the technology. ? In accordance with EMA guidance, the licence for the use of infliximab (Inflectra ® ? ) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence. ? Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade ® ), post-marketing pharmacovigilance is essential

2015 All Wales Medicines Strategy Group

149. Infliximab (Remsima) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis

Infliximab (Remsima) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis Final Appraisal Recommendation Advice No: 4314 – December 2014 Infliximab (Remsima ® ? ) 100 mg powder for concentrate for solution for infusion Submission by Celltrion Healthcare Ltd/Napp Pharmaceuticals Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. ? Please refer to the NICE website for full guidance on NICE (...) recommendations, including any specific restrictions on the use of the technology. ? In accordance with EMA guidance, the licence for the use of infliximab (Remsima ® ? ) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence. ? Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade ® ), post-marketing pharmacovigilance is essential

2015 All Wales Medicines Strategy Group

150. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis Full Text available with Trip Pro

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.We assembled a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018. Exposure was dispensation

2019 EvidenceUpdates

151. Anti-TNF agents for paediatric psoriasis. Full Text available with Trip Pro

Anti-TNF agents for paediatric psoriasis. Psoriasis is a chronic skin disease that may develop at any age. Estimates for the United States and Europe suggest that psoriasis accounts for 4% of skin diseases in children. In most cases, the condition is mild and can be treated with creams. However, a small percentage of children have moderate to severe disease that requires drugs, such as ciclosporin or methotrexate, and some will require injections with newer biological agents, such as anti-TNF (...) (tumour necrosis factor) drugs. Anti-TNF drugs (among them etanercept, infliximab, and adalimumab) are designed to reduce inflammation in the body caused by tumour necrosis factor. Evidence for the safety and efficacy of these biological agents in paediatric psoriasis is lacking.To assess the efficacy and safety of anti-TNF agents for the treatment of paediatric psoriasis.We searched the following databases up to July 2015: the Cochrane Skin Group Specialised Register, the Cochrane Central Register

2015 Cochrane

152. Oral fumaric acid esters for psoriasis. Full Text available with Trip Pro

Oral fumaric acid esters for psoriasis. Psoriasis is a chronic inflammatory skin condition that can markedly reduce life quality. Several systemic therapies exist for moderate to severe psoriasis, including oral fumaric acid esters (FAE). These contain dimethyl fumarate (DMF), the main active ingredient, and monoethyl fumarate. FAE are licensed for psoriasis in Germany but used off-licence in many countries.To assess the effects and safety of oral fumaric acid esters for psoriasis.We searched (...) trials (RCTs) of FAE, including DMF monotherapy, in individuals of any age and sex with a clinical diagnosis of psoriasis.Two review authors independently assessed trial quality and extracted data. Primary outcomes were improvement in Psoriasis Area and Severity Index (PASI) score and the proportion of participants discontinuing treatment due to adverse effects.We included 6 studies (2 full reports, 2 abstracts, 1 brief communication, and 1 letter), with a total of 544 participants. Risk of bias

2015 Cochrane

153. Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants

Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants'', 1 July 2016 {1} {1} {1} | | > > > In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants FREE DOWNLOAD In a trial in 114 children, the efficacy of adalimumab was not notably different from that of methotrexate, and its adverse effects profile did not appear to be more favourable. Full text

2016 Prescrire

154. Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis

Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 1 April 2016 EMA/CHMP/272283/2016 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Flixabi International non (...) in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint CHMP assessment report EMA/CHMP/272283/2016 Page 4/86 damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1). Psoriasis Flixabi is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate

2016 European Medicines Agency - EPARs

155. Taltz (ixekizumab) - Psoriasis

Taltz (ixekizumab) - Psoriasis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 25 February 2016 EMA/CHMP/190631/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Taltz International non-proprietary name (...) NAPSI Nail Psoriasis Severity Index NMSC non-melanoma skin cancer NRI nonresponder imputation NRS Numeric Rating Scale PASI Psoriasis Area and Severity Index PPASI Psoriasis Palmoplantar Severity Index PSAB Psoriasis Skin Appearance Bothersomeness PSSI Psoriasis Scalp Severity Index Q2W every 2 weeks Q4W every 4 weeks Q12W every 12 weeks QIDS-SR16 Quick Inventory of Depressive Symptomatology–Self Report (16 Items) sPGA static Physician Global Assessment TE-ADA treatment-emergent anti-drug antibodies

2016 European Medicines Agency - EPARs

156. Taltz (ixekizumab) - To treat adults with moderate-to-severe plaque psoriasis

Taltz (ixekizumab) - To treat adults with moderate-to-severe plaque psoriasis TALTZ (ixekizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search TALTZ (ixekizumab) Injection TALTZ (ixekizumab) Injection Company: Eli Lilly and Company Application No.: 125521 Approval Date: 03/22/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2016 FDA - Drug Approval Package

157. Umbrella literature review of network meta-analyses (NMAs) in psoriasis

Umbrella literature review of network meta-analyses (NMAs) in psoriasis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2020 PROSPERO

158. Psoriasis: assessment and management

Psoriasis: assessment and management Psoriasis: assessment and management Psoriasis: assessment and management Clinical guideline Published: 24 October 2012 nice.org.uk/guidance/cg153 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psoriasis: assessment and management (CG153) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 57Contents Contents Overview 4 Who is it for? 4 Introduction 5 Patient

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

159. Cosentyx (secukinumab) - To treat adults with moderate-to-severe plaque psoriasis

Cosentyx (secukinumab) - To treat adults with moderate-to-severe plaque psoriasis Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - COSENTYX (secukinumab) Company: Novartis Pharmaceuticals Corporation Application No.: 125504 Approval Date: 1/21/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

160. Betamethasone for Adults with Scalp Psoriasis

Betamethasone for Adults with Scalp Psoriasis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Betamethasone for Adults with Scalp Psoriasis: A Review of the Clinical and Cost

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>